You are here

  • Home
  • Archive
  • Volume 77, Issue 8
  • Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF
Clinical and epidemiological research
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Authors

  1. Correspondence to Professor Loïc Guillevin, Department of Internal Medicine, Hôpital Cochin, Paris 75679, France; loic.guillevin{at}orange.fr
View Full Text

Citation

Charles P, Terrier B, Perrodeau É for the French Vasculitis Study Group, et al
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Annals of the Rheumatic Diseases 2018;77:1143-1149.

Publication history

  • Received December 19, 2017
  • Revised April 6, 2018
  • Accepted April 9, 2018
  • First published April 25, 2018.
Online issue publication 
May 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.